基础医学与临床 ›› 2018, Vol. 38 ›› Issue (12): 1795-1798.

• 短篇综述 • 上一篇    下一篇

甲状腺相关眼病治疗新进展

高艺倬,李辉   

  1. 北京协和医院
  • 收稿日期:2018-08-06 修回日期:2018-10-24 出版日期:2018-12-05 发布日期:2018-11-23
  • 通讯作者: 李辉 E-mail:huilixh@163.com

Progress in the treatment of thyroid associated ophthalmopathy

  • Received:2018-08-06 Revised:2018-10-24 Online:2018-12-05 Published:2018-11-23

摘要: 甲状腺相关眼病(TAO)是一种常见的眼眶疾病,发病率居成人眼眶病之首。传统针对TAO的治疗方式主要有激素治疗、眶周放射治疗及手术治疗。近年来,硒补充治疗、免疫抑制剂、生物制剂等新型治疗方式表现出了较大的潜力。

关键词: 甲状腺相关眼病, 硒补充疗法, 生物制剂, 眶减压手术

Abstract: Thyroid associated ophthalmopathy (TAO) is a familiar disease in orbit, ranking top among the orbital diseases with highest incidence. Traditional treatment includes the use of corticosteroids, radiotherapy and surgical treatment. In recent years, relative researches about selenium, biological immunosuppressive agents have been increased and showed great potential in the treatment of TAO.

Key words: Thyroid associated ophthalmopathy, Selenium supplement therapy, Biological agents, Orbital decompression

中图分类号: